Scientists at the Massachusetts Institute of Technology (MIT) have engineered Bacteroides thetaiotaomicron - one of the most common bacteria in the human gut - with new functions.
The manipulated bacteria were re-introduced into the intestinal tract of a mouse.
The study, appearing in the journal Cell Systems, is a starting point for designing microbes that could eventually deliver drugs or detect long-term changes in the intestines that lead to inflammatory bowel disease or other illnesses.
The idea to bio-engineer bacteria for therapeutic purposes is not new, but not all bacteria are suited for the same tasks.
The MIT group, led by synthetic biologists Timothy K. Lu and Christopher Voigt, saw that Bacteroides had the potential to express genes on demand.
"The bacteria that live in us or on us impact human health in very significant ways and we have techniques to modulate the microbiome - taking antibiotics or changing our diet -- are relatively limited," said Timothy K. Lu.
"We're hoping that with these tools to precisely engineer the intimate interface between bacteria and humans we're going to be able to tackle some major health-related problems," he said.
The eventual goal would be to engineer microbes that can alter gene expression based on signals within the intestines in humans.
"Not only you have an engineered bacterium that has colonised the mouse gut, but you can turn on which genes in the bacterium are active based on what you feed the mouse," said Christopher Voigt.
"That's really something new. It allows you to control what the bacterium is doing at the site of where it's operating," he said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
